Zura Bio Limited (ZURA)
1.36
0.16 (13.33%)
At close: Feb 28, 2025, 3:59 PM
1.36
0.00%
After-hours: Feb 28, 2025, 04:00 PM EST
Company Description
Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders.
It develops ZB-168, an anti IL7R a inhibitor that impact on diseases driven by IL7 and TSLP biological pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.
The company is based in San Diego, California.
Zura Bio Limited

Country | United States |
IPO Date | Mar 21, 2023 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 14 |
CEO | Robert Lisicki |
Contact Details
Address: 4225 Executive Square San Diego, California United States | |
Website | https://zurabio.com |
Stock Details
Ticker Symbol | ZURA |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001855644 |
CUSIP Number | n/a |
ISIN Number | KYG9TY5A1016 |
Employer ID | 00-0000000 |
SIC Code | 2836 |
Key Executives
Name | Position |
---|---|
Robert Lisicki | Chief Executive Officer & Director |
Dr. Gary Whale Ph.D. | Chief Technology Officer |
Kimberly Ann Davis | Chief Legal Officer & Corporate Secretary |
Verender S. Badial | Chief Financial Officer |
David Brady | Head of Business Development |
Dr. Kiran Nistala MBBS, Ph.D. | Chief Medical Officer & Head of Development |
Dr. Someit Sidhu M.D. | Founder & Director |
Theresa Lowry | Chief Human Resources Officer |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Feb 24, 2025 | 8-K | Current Report |
Feb 14, 2025 | SCHEDULE 13G/A | [Amend] Filing |
Feb 14, 2025 | SCHEDULE 13G/A | [Amend] Filing |
Feb 14, 2025 | SCHEDULE 13G/A | [Amend] Filing |
Feb 14, 2025 | 5 | Filing |
Feb 14, 2025 | 5 | Filing |
Feb 12, 2025 | SCHEDULE 13G/A | [Amend] Filing |
Jan 13, 2025 | 8-K | Current Report |
Dec 31, 2024 | 4 | Filing |
Dec 23, 2024 | 8-K | Current Report |